Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Trial details
- Registry ID
- NCT04615949
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as CardiolRx
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949 | CRDL | Phase 2, Phase 3 | Terminated | 2022-11-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |